Special networking session with the biotechnology industry

Monday, 5 March 2018, 13:00 – 14:30
Agenda – Today’s opportunity

Who’s in the room?
– Welcome from the IAS and roundtable introductions
  Anton Pozniak / Owen Ryan

How can we work together?
– IAS Industry Liaison Forum & other programmatic entry points
  Jürgen Rockstroh / Duncan Blair / Helen McDowell

What’s taking place in Amsterdam in July?
– 22nd International AIDS Conference (AIDS 2018)
  Linda-Gail Bekker

What are yours and the HIV biomedical industry’s greatest challenges?
– Group discussion
  Owen Ryan
IAS – What we do

Science
Pushing for the full spectrum of scientific achievement – from basic science to implementation research – and using IAS’ convening power to highlight dynamic, innovative work

People
Ensuring that those responsible for putting science into practice – researchers, physicians, nurses, laboratory workers, community workers and civil society – have the resources they need to do their job

Progress
Driving rapid and sustainable improvement in health outcomes by using IAS’ scientific authority to move science into policy and policy into tangible impact against the epidemic
IAS – Conferences & programmes

International AIDS Conference – AIDS 2018 / Amsterdam

- World’s largest conference on any global health or development issue (bringing together 15,000-18,000 delegates)
- Unique forum for the intersection of science, policy and human rights that regularly leads to significant global and national policy change

HIV Programmes and Advocacy – Policy, research, structural barriers
The IAS Industry Liaison Forum works to promote and facilitate the full contribution of the biomedical industry to the global HIV response.

By organizing a number of bespoke meetings on key topic areas, the ILF brings to the foreground the contribution of an interdisciplinary group on current and emerging issues.

The ILF also builds on its collaboration platform to address a range of issues in paediatric HIV and regulatory affairs.

Catalyses dialogue and engagement

Focuses on paediatric HIV and regulatory affairs

Involves a diverse, multi-stakeholder advisory group

Addresses barriers along the HIV cascade

Highlights the perspective of the biomedical industry
ILF – Discussing PrEP

This roundtable will review the latest information on PrEP rollout and provide a state-of-the-art overview of the molecules currently under development as long-acting PrEP and in Phase I, II, and III clinical trials.

This will set the stage for an engaging, interactive discussion of remaining challenges and promising approaches for long-acting PrEP clinical trials and regulatory approval in adults and youth (including neonatal prophylaxis).
ILF – Corporate partners and advisory Group

ILF IAS Governing Council Co-Chair
Kenneth Mayer – (The Fenway Institute, USA)

ILF Industry Co-Chair
Duncan Blair – (Abbott, Switzerland)

Industry Advisory Group members

Gold Corporate Partners
- Gilead Sciences
- Janssen
- MSD
- ViV Healthcare

Silver Corporate Partners
- AbbVie
- Abbott

Bronze Corporate Partners
- Beckman Coulter
- Cepheid
- Cipla
- Coral Healthcare
- Lupin
- Omega Diagnostics
- Roche Molecular Systems
- Sysmex Corporation

Non-Industry Advisory Group members

IAS Governing Council
- Desmond Tutu HIV Foundation
- Johns Hopkins University
- The Fenway Institute
- U. Federal do Rio de Janeiro
- U. of Bonn
- U. of the West Indies

Regulatory / normative agencies
- FDA
- WHO Prequalification
- Global Fund
- Lindo-Gail Bekker – South Africa
- Chris Beyrer – USA
- Kenneth Mayer – USA
- Mauro Schechter – Brazil
- Jürgen Rockstroh – Germany
- Celia Christie-Samuels – Jamaica
- Jeffrey Murray – USA
- Matthias Stahl – Switzerland
- Martin Auton – Switzerland

Procurement / implementing organizations
- Medicines Patent Pool
- UNITAID
- WHO HIV/AIDS Department
- Sandeep Juneja – Switzerland
- Philippe Duneton – Switzerland
- Boniface Dongmo Ngumfack – Switzerland
- Catherine Hanks – The Netherlands
- Nicholas Hellman – USA
- Elliot Cowan – USA
- Colleen Daniels – Australia

Experts in IAS Priorities or other issues
- AIGHD
- EPGAF
- Partners in Diagnostics
- CD Global Consulting
- Wim Vandevelde – South Africa
- Rahab Mwariki – Kenya
- Brent Allan – Australia

Civil society
- GNP+
- NEPHAK
- ASHM & ICASO
WHO PQDx is a valuable initiative that improves the quality of in vitro diagnostics for under-served populations in countries where regulatory systems are weak or non-existent.

However, broader attention to some of the existing inefficiencies and longer-term risks concerning the successful implementation of this important programme is needed.

Our viewpoint discussed challenges of WHO PQDx, in particular around its scope, processes, timelines and financing. It also highlights the manufacturers’ responsibilities.
ILF – Global Accelerator for Paediatric Formulations

Limited treatment options and sub-optimal formulations have contributed to poor adherence and outcomes for children living with HIV. Despite the need for expanded and improved options for paediatric treatment, significant structural and technical barriers to ensuring that the most needed formulations are developed for children remain.

The GAP-f is a collaborative framework that aims to expedite development and uptake of priority paediatric formulations for key disease areas facing similar market challenges, such as HIV, TB, viral hepatitis and antimicrobials.
ILF – Addressing stock outs in Venezuela

There is currently an important public health crisis in Venezuela, of which the impact on the HIV response has been described in a recent report by ICASO: Triple threat: Resurging epidemics, a broken health system, and global indifference to Venezuela’s crisis. The needs for HIV diagnostics and medicines are urgent.

In collaboration with ICASO and ViiV Healthcare, the ILF convened a discussion on biomedical industry actions to address the stock outs of HIV and other health commodities in Venezuela.
CIPHER – Building the next generation of researchers and informing policy

In a context of reduced funding, opportunities for young investigators from low- and middle-income countries are needed. CIPHER’s approach to addressing research gaps focuses on capacity building for the next generation of researchers in pediatric and adolescent HIV in these settings.

As the largest collaboration of pediatric and adolescent HIV observational cohorts to date, the CIPHER Global Cohort Collaboration works together to answer key questions of global public health impact that cannot be answered by one network alone.
AIDS 2018 – 23-27 July, Amsterdam

• 18,000+ scientists, clinicians, programme implementers, policy makers, funders, advocates meet to discuss groundbreaking science and review progress against 2030 target of eliminating AIDS

• 800+ journalists reporting across major global media

• A best-in-class programme with more than 500 sessions, workshops and activities

• Strong pre-conference programme, including STI 2018 and TB 2018
Join us in Amsterdam

- Showcase your products and services to a **large relevant audience** of programme implementers, funders, scientists and the community at a **world class conference centre** with excellent opportunities for exhibiting and branding

- Expand your network of contacts through excellent opportunities to **engage with clients and partners**

- Learn **new trends, data, and research**

- Demonstrate your commitment to the HIV response: **Be recognized** on the conference website, in print documents and through social media with a reach to more than **70,000 people** through direct conference channels
Open floor discussion –
*What are your and the HIV biomedical industry’s greatest challenges?*
Thank you